董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Reza Zadno | 男 | President, Chief Executive Officer and Director | 66 | 355.54万美元 | 未持股 | 2021-07-31 |
| Taylor Harris | 男 | Director | 45 | 20.10万美元 | 未持股 | 2021-07-31 |
| Frederic Moll | 男 | Director and Chair of the Board | 69 | 3.50万美元 | 未持股 | 2021-07-31 |
| Amy Dodrill | 女 | Director | 48 | 未披露 | 未持股 | 2021-07-31 |
| Antal Desai | 男 | Director | 43 | 未披露 | 未持股 | 2021-07-31 |
| Thomas Krummel | 男 | Director | 69 | 4.25万美元 | 未持股 | 2021-07-31 |
| Colby Wood | 男 | Director | 50 | 4.22万美元 | 未持股 | 2021-07-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alaleh Nouri | 女 | SVP, General Counsel & Corporate Secretary | 42 | 未披露 | 未持股 | 2021-07-31 |
| Reza Zadno | 男 | President, Chief Executive Officer and Director | 66 | 355.54万美元 | 未持股 | 2021-07-31 |
| Kevin Waters | 男 | SVP, Chief Financial Officer | 44 | 73.50万美元 | 未持股 | 2021-07-31 |
| Hisham Shiblaq | 男 | SVP, Global Commercialization | 46 | 58.20万美元 | 未持股 | 2021-07-31 |
董事简历
中英对照 | 中文 | 英文- Reza Zadno
-
Reza Zadno从2013年3月开始一直担任我司董事。Zadno博士从2015年1月开始担任风险投资公司InterWest Partners的驻企高管。从2012年1月到2014年12月，他在该公司担任风险合伙人。从2011年1月到2012年1月，Zadno博士担任风险投资公司New Leaf Venture Partners的风险合伙人。从2001年3月到2009年9月，Zadno博士是医疗设备公司Visiogen的创始人、总裁和首席执行官，该公司于2009年被医学设备公司雅培医疗光学（Abbott-Medical Optics）收购，Zadno博士从此时担任其总经理直到2011年1月。Zadno博士目前担任几家私人所有的生命科学公司的董事。Zadno博士在巴黎矿业大学（Ecole des Mines）获得医生——工程师博士学位。
Reza Zadno has served as our President and Chief Executive Officer and a member of our board of directors since February 2020. He previously served as President and Chief Executive Officer of Avedro, Inc., a healthcare company, from September 2016 to November 2019 where he also served as a member of the board of directors from September 2016 to November 2020. Dr. Zadno also previously served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017 where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016 where he was a member of the audit committee, in addition to a number of private companies. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from Ecole Nationale Superieure des Mines de Paris. - Reza Zadno从2013年3月开始一直担任我司董事。Zadno博士从2015年1月开始担任风险投资公司InterWest Partners的驻企高管。从2012年1月到2014年12月，他在该公司担任风险合伙人。从2011年1月到2012年1月，Zadno博士担任风险投资公司New Leaf Venture Partners的风险合伙人。从2001年3月到2009年9月，Zadno博士是医疗设备公司Visiogen的创始人、总裁和首席执行官，该公司于2009年被医学设备公司雅培医疗光学（Abbott-Medical Optics）收购，Zadno博士从此时担任其总经理直到2011年1月。Zadno博士目前担任几家私人所有的生命科学公司的董事。Zadno博士在巴黎矿业大学（Ecole des Mines）获得医生——工程师博士学位。
- Reza Zadno has served as our President and Chief Executive Officer and a member of our board of directors since February 2020. He previously served as President and Chief Executive Officer of Avedro, Inc., a healthcare company, from September 2016 to November 2019 where he also served as a member of the board of directors from September 2016 to November 2020. Dr. Zadno also previously served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017 where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016 where he was a member of the audit committee, in addition to a number of private companies. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from Ecole Nationale Superieure des Mines de Paris.
- Taylor Harris
-
Taylor Harris，曾一直担任首席财务官兼高级副总裁（2016年4月以来），然而，他于2016年3月加入公司，作为兼职蚕丝额副总裁。他此前曾担任Thoratec Corporation的副总裁兼首席财务官（2012年10月至2015年10月），期间他曾负责所有金融、会计、财政和投资者关系功能。Thoratec公司于2015年10月被St. Jude Medical, Inc收购。他于2010年2月加入Thoratec公司，担任投资者关系和商业开发的高级主管，负责开发和执行公司的投资者关系战略，并支持该公司的战略和业务开发活动。在加入Thoratec之前，他在摩根大通公司（JPMorgan Chase & Co。）担任各种职务10年多，包括副总裁，负责公司的医疗保健投资银行和股票研究部门。他获得教堂山的北卡罗莱纳大学（the University of North Carolina）的物理和经济学学士学位。
Taylor Harris has served as a member of our board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company’s acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill. - Taylor Harris，曾一直担任首席财务官兼高级副总裁（2016年4月以来），然而，他于2016年3月加入公司，作为兼职蚕丝额副总裁。他此前曾担任Thoratec Corporation的副总裁兼首席财务官（2012年10月至2015年10月），期间他曾负责所有金融、会计、财政和投资者关系功能。Thoratec公司于2015年10月被St. Jude Medical, Inc收购。他于2010年2月加入Thoratec公司，担任投资者关系和商业开发的高级主管，负责开发和执行公司的投资者关系战略，并支持该公司的战略和业务开发活动。在加入Thoratec之前，他在摩根大通公司（JPMorgan Chase & Co。）担任各种职务10年多，包括副总裁，负责公司的医疗保健投资银行和股票研究部门。他获得教堂山的北卡罗莱纳大学（the University of North Carolina）的物理和经济学学士学位。
- Taylor Harris has served as a member of our board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company’s acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill.
- Frederic Moll
-
Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
Frederic Moll has served as a member of our board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington. - Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
- Frederic Moll has served as a member of our board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington.
- Amy Dodrill
-
Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of our U.S. Surgical Solutions sales operations and prior to that, as an area vice president in our Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare. - Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
- Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of our U.S. Surgical Solutions sales operations and prior to that, as an area vice president in our Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare.
- Antal Desai
-
Antal Desai自2015年6月起担任我们的董事会成员。他于2004年9月加入Cardinal Investment Company，Inc.（CPMG，Inc.的前身公司），这是一家投资公司，在全球范围内投资上市和私人公司，如果他目前担任合伙人的话。德赛先生是几家私人公司的董事。德赛在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得经济学学士学位和MBA学位。
Antal Desai has served as a member of our board of directors since June 2015. Mr. Desai joined Cardinal Investment Company, Inc. in September 2004 the predecessor firm to CPMG, Inc., an investment firm that invests in publicly-traded and private companies globally, were he currently serves as a Partner. Mr. Desai is a director at several private companies. Mr. Desai received both a B.S. in Economics and an M.B.A. from the Wharton School at the University of Pennsylvania. - Antal Desai自2015年6月起担任我们的董事会成员。他于2004年9月加入Cardinal Investment Company，Inc.（CPMG，Inc.的前身公司），这是一家投资公司，在全球范围内投资上市和私人公司，如果他目前担任合伙人的话。德赛先生是几家私人公司的董事。德赛在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得经济学学士学位和MBA学位。
- Antal Desai has served as a member of our board of directors since June 2015. Mr. Desai joined Cardinal Investment Company, Inc. in September 2004 the predecessor firm to CPMG, Inc., an investment firm that invests in publicly-traded and private companies globally, were he currently serves as a Partner. Mr. Desai is a director at several private companies. Mr. Desai received both a B.S. in Economics and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Thomas Krummel
-
Thomas Krummel自2010年12月起担任董事会成员。Krummel博士自1998年10月起担任斯坦福大学教授，自2021年3月起担任Santé；Ventures（一家早期医疗技术投资公司）风险合伙人。自2010年7月以来，他一直是加利福尼亚水务公司的董事会成员，在那里他担任提名公司治理委员会的成员，并担任薪酬委员会的主席，此外还担任许多私人公司的董事。Krummel博士在威斯康星大学帕克赛德分校获得化学学士学位，在威斯康星医学院获得医学博士学位。
Thomas Krummel has served as a member of our board of directors since December 2010. Since October 1998 Dr. Krummel has been a professor at Stanford University and has served as Venture Partner at Santé Ventures, an early stage medical technology investment firm, since March 2021. He has been a member of the board of directors of California Water Service Group since July 2010 where he serves as a member of the Nominating Corporate Governance committee and serves as Chair of the Compensation committee, in addition to a number of private companies. Dr. Krummel received a B.S. in Chemistry from University of Wisconsin at Parkside and an M.D. from the Medical College of Wisconsin. - Thomas Krummel自2010年12月起担任董事会成员。Krummel博士自1998年10月起担任斯坦福大学教授，自2021年3月起担任Santé；Ventures（一家早期医疗技术投资公司）风险合伙人。自2010年7月以来，他一直是加利福尼亚水务公司的董事会成员，在那里他担任提名公司治理委员会的成员，并担任薪酬委员会的主席，此外还担任许多私人公司的董事。Krummel博士在威斯康星大学帕克赛德分校获得化学学士学位，在威斯康星医学院获得医学博士学位。
- Thomas Krummel has served as a member of our board of directors since December 2010. Since October 1998 Dr. Krummel has been a professor at Stanford University and has served as Venture Partner at Santé Ventures, an early stage medical technology investment firm, since March 2021. He has been a member of the board of directors of California Water Service Group since July 2010 where he serves as a member of the Nominating Corporate Governance committee and serves as Chair of the Compensation committee, in addition to a number of private companies. Dr. Krummel received a B.S. in Chemistry from University of Wisconsin at Parkside and an M.D. from the Medical College of Wisconsin.
- Colby Wood
-
Colby Wood自2014年2月起担任董事会成员。自2018年3月起，Wood先生一直担任Sonder Capital Management，LLC（一家医疗保健风险投资公司）的管理合伙人。在此之前，Wood先生从2011年12月到2017年12月担任Oechsle International Advisors，Ltd.（一家国际投资顾问公司）的投资组合经理和股票分析师。伍德先生目前在两家私人公司的董事会任职。伍德先生在特拉华大学获得英语学士学位，在巴布森学院F.W.Olin商学院获得工商管理硕士学位。
Colby Wood has served as a member of our board of directors since February 2014. Since March 2018 Mr. Wood has been a Managing Partner at Sonder Capital Management, LLC, a healthcare venture capital investment firm. Prior to this, Mr. Wood was a Portfolio Manager and Equity Analyst at Oechsle International Advisors, Ltd., an international investment advisors, from December 2011 to December 2017. Mr. Wood currently serves on the board of directors for two private companies. Mr. Wood received his B.A. in English from University of Delaware and M.B.A. from F.W. Olin Graduate School of Business at Babson College. - Colby Wood自2014年2月起担任董事会成员。自2018年3月起，Wood先生一直担任Sonder Capital Management，LLC（一家医疗保健风险投资公司）的管理合伙人。在此之前，Wood先生从2011年12月到2017年12月担任Oechsle International Advisors，Ltd.（一家国际投资顾问公司）的投资组合经理和股票分析师。伍德先生目前在两家私人公司的董事会任职。伍德先生在特拉华大学获得英语学士学位，在巴布森学院F.W.Olin商学院获得工商管理硕士学位。
- Colby Wood has served as a member of our board of directors since February 2014. Since March 2018 Mr. Wood has been a Managing Partner at Sonder Capital Management, LLC, a healthcare venture capital investment firm. Prior to this, Mr. Wood was a Portfolio Manager and Equity Analyst at Oechsle International Advisors, Ltd., an international investment advisors, from December 2011 to December 2017. Mr. Wood currently serves on the board of directors for two private companies. Mr. Wood received his B.A. in English from University of Delaware and M.B.A. from F.W. Olin Graduate School of Business at Babson College.
高管简历
中英对照 | 中文 | 英文- Alaleh Nouri
Alaleh Nouri，2014年8月起，她担任我公司高级副总裁、总法律顾问和公司秘书。2010年12月至2014年2月，她担任我公司副总裁、助理总法律顾问；2014年2月至7月，担任我公司临时总法律顾问。2009年3月至2010年12月，她担任Mirion Technologies, Inc.的公司顾问， 该公司是雷达探测与监督设备供应商。她在律师事务所Orrick, Herrington & Sutcliffe LLP担任助理律师，开始职业生涯。她在加拿大英属哥伦比亚大学（University of British Columbia）获得国际商学和金融学士学位，在加利福尼亚大学黑斯廷斯法学院（University of California, Hastings College of Law）获得法学博士学位。
Alaleh Nouri has served as our SVP, General Counsel & Corporate Secretary since July 2018. She previously served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Incorporated, a radiation oncology company, from February 2014 to July 2018. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a Finance specialization from the University of British Columbia.- Alaleh Nouri，2014年8月起，她担任我公司高级副总裁、总法律顾问和公司秘书。2010年12月至2014年2月，她担任我公司副总裁、助理总法律顾问；2014年2月至7月，担任我公司临时总法律顾问。2009年3月至2010年12月，她担任Mirion Technologies, Inc.的公司顾问， 该公司是雷达探测与监督设备供应商。她在律师事务所Orrick, Herrington & Sutcliffe LLP担任助理律师，开始职业生涯。她在加拿大英属哥伦比亚大学（University of British Columbia）获得国际商学和金融学士学位，在加利福尼亚大学黑斯廷斯法学院（University of California, Hastings College of Law）获得法学博士学位。
- Alaleh Nouri has served as our SVP, General Counsel & Corporate Secretary since July 2018. She previously served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Incorporated, a radiation oncology company, from February 2014 to July 2018. Ms. Nouri received a J.D. from U.C. Hastings College of Law and a Bachelor of Commerce in International Business and also completed the requirements for a Finance specialization from the University of British Columbia.
- Reza Zadno
Reza Zadno从2013年3月开始一直担任我司董事。Zadno博士从2015年1月开始担任风险投资公司InterWest Partners的驻企高管。从2012年1月到2014年12月，他在该公司担任风险合伙人。从2011年1月到2012年1月，Zadno博士担任风险投资公司New Leaf Venture Partners的风险合伙人。从2001年3月到2009年9月，Zadno博士是医疗设备公司Visiogen的创始人、总裁和首席执行官，该公司于2009年被医学设备公司雅培医疗光学（Abbott-Medical Optics）收购，Zadno博士从此时担任其总经理直到2011年1月。Zadno博士目前担任几家私人所有的生命科学公司的董事。Zadno博士在巴黎矿业大学（Ecole des Mines）获得医生——工程师博士学位。
Reza Zadno has served as our President and Chief Executive Officer and a member of our board of directors since February 2020. He previously served as President and Chief Executive Officer of Avedro, Inc., a healthcare company, from September 2016 to November 2019 where he also served as a member of the board of directors from September 2016 to November 2020. Dr. Zadno also previously served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017 where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016 where he was a member of the audit committee, in addition to a number of private companies. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from Ecole Nationale Superieure des Mines de Paris.- Reza Zadno从2013年3月开始一直担任我司董事。Zadno博士从2015年1月开始担任风险投资公司InterWest Partners的驻企高管。从2012年1月到2014年12月，他在该公司担任风险合伙人。从2011年1月到2012年1月，Zadno博士担任风险投资公司New Leaf Venture Partners的风险合伙人。从2001年3月到2009年9月，Zadno博士是医疗设备公司Visiogen的创始人、总裁和首席执行官，该公司于2009年被医学设备公司雅培医疗光学（Abbott-Medical Optics）收购，Zadno博士从此时担任其总经理直到2011年1月。Zadno博士目前担任几家私人所有的生命科学公司的董事。Zadno博士在巴黎矿业大学（Ecole des Mines）获得医生——工程师博士学位。
- Reza Zadno has served as our President and Chief Executive Officer and a member of our board of directors since February 2020. He previously served as President and Chief Executive Officer of Avedro, Inc., a healthcare company, from September 2016 to November 2019 where he also served as a member of the board of directors from September 2016 to November 2020. Dr. Zadno also previously served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017 where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016 where he was a member of the audit committee, in addition to a number of private companies. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from Ecole Nationale Superieure des Mines de Paris.
- Kevin Waters
Kevin Waters，2015年9月起，担任本公司的高级副总裁、首席财务官；此前，2013年10月至2015年9月，担任本公司的高级财务副总裁。2008年1月至2013年10月，他担任上市企业 Conceptus, Inc.的财务副总裁，该公司为女性医疗保健提供创新的解决方案，后来被Bayer收购。2006年10月至2008年1月，他是Conceptus的企业财务总监。此前，他担任Laserscope, Inc.的企业财务总监，这是泌尿学和美学激光产品制造商。此前，他在VISX, Incorporated担任过各种财务领导职位，这是激光视力矫正技术制造商。他在PricewaterhouseCoopers, LLP开启职业生涯。他在Cal Poly San Luis Obispo获得财务和会计方向的工商管理学士学位。
Kevin Waters has served as our SVP, Chief Financial Officer since October 2018. He previously served as Chief Financial Officer at Accuray Incorporated, a radiation oncology company, from September 2015 to October 2018 and as its SVP, Finance from October 2013 to August 2015. Mr. Waters received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.- Kevin Waters，2015年9月起，担任本公司的高级副总裁、首席财务官；此前，2013年10月至2015年9月，担任本公司的高级财务副总裁。2008年1月至2013年10月，他担任上市企业 Conceptus, Inc.的财务副总裁，该公司为女性医疗保健提供创新的解决方案，后来被Bayer收购。2006年10月至2008年1月，他是Conceptus的企业财务总监。此前，他担任Laserscope, Inc.的企业财务总监，这是泌尿学和美学激光产品制造商。此前，他在VISX, Incorporated担任过各种财务领导职位，这是激光视力矫正技术制造商。他在PricewaterhouseCoopers, LLP开启职业生涯。他在Cal Poly San Luis Obispo获得财务和会计方向的工商管理学士学位。
- Kevin Waters has served as our SVP, Chief Financial Officer since October 2018. He previously served as Chief Financial Officer at Accuray Incorporated, a radiation oncology company, from September 2015 to October 2018 and as its SVP, Finance from October 2013 to August 2015. Mr. Waters received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.
- Hisham Shiblaq
Hisham Shiblaq自2019年3月起担任我们的全球商业化副总裁。他此前曾担任Invuity，Inc.（医疗设备公司）的商业运营副总裁（从2017年1月到2019年1月），以及Analogic Corporation的销售副总裁（从2016年6月到2017年1月）。Shiblaq先生获得俄亥俄州立大学心理学学士学位。
Hisham Shiblaq has served as our SVP, Global Commercialization since March 2019. He previously served as Vice President of Commercial Operations at Invuity, Inc., a medical device company, from January 2017 to January 2019 and as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.- Hisham Shiblaq自2019年3月起担任我们的全球商业化副总裁。他此前曾担任Invuity，Inc.（医疗设备公司）的商业运营副总裁（从2017年1月到2019年1月），以及Analogic Corporation的销售副总裁（从2016年6月到2017年1月）。Shiblaq先生获得俄亥俄州立大学心理学学士学位。
- Hisham Shiblaq has served as our SVP, Global Commercialization since March 2019. He previously served as Vice President of Commercial Operations at Invuity, Inc., a medical device company, from January 2017 to January 2019 and as Vice President of Sales at Analogic Corporation from June 2016 to January 2017. Mr. Shiblaq received a B.A. in Psychology from Ohio State University.